Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)

NCT01469169 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01469169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01469169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2012
Completion date
December 14, 2016
Enrollment
27 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary